Histopathological and biochemical effect of Liv-52 on rifampicin and isoniazid induced liver toxicity in adult albino rats

Hans Lwunza Libamila

doi:10.18203/2320-6012.ijrms20241217

Authors

Hans Lwunza Libamila Department of Human Anatomy, School of Medicine, Maseno University, Maseno, Kenya

DOI:

https://doi.org/10.18203/2320-6012.ijrms20241217

Keywords:

Hepatotoxicity, Hepatoprotective, Histopathology, Isoniazide, Rifampicin, Deranged

Abstract

Background: Rifampicin and Isoniazid are two main medicinal drugs used as regimen in the treatment of Tuberculosis. These drugs induce hepatotoxicity. Liv-52, a polyherbal formulation has been shown to have clinical use in the treatment of liver disorders. The aim of this study was to investigate the histopathological and biochemical effects of Liv-52 on INH and RIF induced hepatotoxicity.

Methods: Adult albino rats weighing 150g to 250g were used. A total of 24 rats were randomly assigned into 4 groups of 6 rats each. Group 1 served as negative control. Hepatotoxicity was achieved by administering 50 mg/kg/day of RIF and INH each as positive control. Hepatoprotective effect was determined by administering Liv-52 concurrently with positive control. Low dose Liv-52 and high dose Liv-52 was administered at (155 mg/kg/day and 207 mg/kg/day) respectively, concurrently with RIF and INH at (50 mg/kg) each orally daily. After 21 days, the albino rats were sacrificed humanely, liver harvested and blood samples taken for estimation of liver serum biomarkers. The livers were processed and stained with Haematoxylin and Eosin for histological examination. Significance levels of (p≤0.05).

Results: The three selected liver biochemical parameters (ALT, AST and ALP) significantly increased in positive control group relative to negative control. The hepatoprotective groups (especially the HD Liv-52 group) showed significant reduction in the biochemical parameters. The liver histopathological results confirmed the above findings.

Conclusion: High dose Liv-52 significantly prevents hepatotoxicity induced by antitubercular therapy by inhibiting rise liver biochemical parameters and also ameliorating the deranged liver histomorphological features.

Metrics

Metrics Loading ...

References

Gulati K, Reshi MR, Rai N, Ray A. Hepatotoxicity: Its mechanisms, experimental evaluation and protective strategies. Am J Pharmacol. 2018;1(1): 1004.

Maity TA, Ahmad AY. Protective effect of Mikania scandens (L.) willd. against isoniazid induced hepatotoxicity in rats. Int J Pharm Pharm Sci. 2012; 4(3):466-9.

Choijamts G, Batsyren C, Orkhon B, Otgontyr DN, Oyunerdene X, Zagirjav T, et al. Role of Liv. 52 DS tablets as a hepatoprotective agent in tuberculosis patients receiving antitubercular drugs: A double blind placebo controlled study. J. Liver Clinical Res. 2018;5:1042-50.

Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, et al. Antituberculosis drug‐related liver dysfunction in chronic hepatitis B infection. Hepatology. 2000;31(1):201-6.

Devarbhavi H. Antituberculous drug-induced liver injury: current perspective. Tropical Gastroenterology. 2011;32(3):167-74.

Saha A, Shanthi FXM, Winston AB, Das S, Kumar A, Michael JS, et al. Prevalence of hepatotoxicity from antituberculosis therapy: a five-year experience from South India. J Prim Care Community Health. 2016; 7(3):171-4.

Pullan ST, Allnutt JC, Devine R, Hatch KA, Jeeves RE, Hendon-Dunn CL, et al. The effect of growth rate on pyrazinamide activity in Mycobacterium tuberculosis-insights for early bactericidal activity?. BMC Infect Dis. 2016;16(1):1.

Wang P, Pradhan K, Zhong XB, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharmaceut Sinica B. 2016;6(5):384-92.

Yew WW, Lee J, Wong PC, Kwan SY. Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction. Int J Clin Pharmacol Res. 1992;12(4):173-8.

Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Resp J. 1996;9(10):2026-30.

Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, Feng Y. The role of oxidative stress and antioxidants in liver diseases. Int J Mol Sci. 2015;16(11):26087-124.

Arif IS, Raoof IB, Luaibi HH, Ibraheem SK. Role of miRNA in drug-induced hepatic injury. AJPS. 2022;5:1.

Sankar M, Rajkumar J, Sridhar D. Hepatoprotective activity of heptoplus on isoniazid and rifampicin induced liver damage in rats. Indian J Pharma Sci. 2015;77(5):556.

Sapakal VD, Ghadge RV, Adnaik RS, Naikwade NS, Magdum CS. Comparative hepatoprotective activity of Liv-52 and livomyn against carbon tetrachloride-induced hepatic injury in rats. Int J Green Pharma. 2008;2(2):32-8.

Usmani A, Mujahid MD, Khushtar M, Siddiqui HH, Rahman MA. Hepatoprotective effect of Anacyclus pyrethrum Linn. against antitubercular drug-induced hepatotoxicity in SD rats. J Complement Integrat Med. 2016;13(3):295-300.

Chen X, Xu J, Zhang C, Yu T, Wang H, Zhao M. The protective effects of ursodeoxycholic acid on isoniazid plus rifampicin induced liver injury in mice. Eur J Pharmacol. 2011;659(1):53-60.

Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Resp Crit Care Med. 2006;174(8):935-52.

Parameswari SA, Chetty CM, Chandrasekhar KB. Hepatoprotective activity of Ficus religiosa leaves against isoniazid+rifampicin and paracetamol induced hepatotoxicity. Pharmacognosy Res. 2013;5(4):271-6.

Fulzele VB, Shedage AT, Smith AA, Gaikwad TV, Kirtane SR. Comparative hepatoprotective activity of liv-52 and silymarine against hepatotoxicity induced by antiandrogen-bicalutamide in rats. Pharmacognosy Res. 2012;2(28):4600.

Huseini HF, Alavian SM, Heshmat R, Heydari MR, Abolmaali K. The efficacy of Liv-52 on liver cirrhotic patients: a randomized, double-blind, placebo-controlled first approach. Phytomedicine. 2005;12(9): 619-24.

Cimen O, Eken H, Keskin Cimen F, Cekic AB, Kurt N, Ozbek Bilgin A, et al. The effect of Liv-52 on liver ischemia reperfusion damage in rats. BMC Pharmacol Toxicol. 2020;21(1):1-9.

Dubiwak AD, Damtew TW, Senbetu MW, Yewhalaw D, Asere TG, Nemo G, et al. Hepatoprotective effect of corm of Ensete ventricosum (welw.) cheesman extract against isoniazid and rifampicin induced hepatotoxicity in Swiss albino mice. J Toxicol. 2021; 13:2021.

Sabina EP, Peter S J, Geetha A. A comparison of hepatoprotective activity of Bacoside to Silymarin treatment against a combined Isoniazid and Rifampin-induced hepatotoxicity in female Wistar rats. J Histotechnol. 2019;42(3):128-36.

Shabbir M, Afsar T, Razak S, Almajwal A, Khan MR. Phytochemical analysis and Evaluation of hepatoprotective effect of Maytenus royleanus leaves extract against anti-tuberculosis drug induced liver injury in mice. Lipids Health Dis. 2020;19:1-5.

Rashid MS. Histological effect of isoniazid drug in the kidney and liver tissues of albino mice Mus Musuclus. Tikrit J Pure Sci. 2021;26(5):27-33.